Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.30 |
| ▸ | ACE | P12821 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007257 | 0.89 | ACHE (0.32) | CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL3012494 | 0.77 | CYP11B1 (0.35) | CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL3014473 | 0.75 | GABRA1 (0.35) | CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL3014230 | 0.74 | ICMT (0.45) | — | |
| SCHEMBL3001145 | 0.72 | ICMT (0.47) | — | |
| SCHEMBL3009279 | 0.72 | ALDH1A1 (0.36) | CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL2892358 | 0.70 | CHRM5 (0.43) | — | |
| SCHEMBL2999032 | 0.69 | CPB2 (0.41) | — | |
| SCHEMBL9267101 | 0.68 | CYP11B1 (0.58) | CYP11B1CYP11B2 | |
| SCHEMBL27781544 | 0.67 | ACHE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2167474-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | Valletta Health IP EE B.V. (NL) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153385-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH B.V. (NL) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | CYP11B1 1429/4885CYP11B2 2098/4885TBXAS1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.